Background
==========

Breast cancer is the most frequent malignancy among women \[[@B1]\], and the presence of a family history is one of the most fundamental risk factors for the disease \[[@B2]\]. Currently known susceptibility genes including *BRCA1, BRCA2, ATM, CHEK2, PALB2, RAD51C*and *BRIP1*explain less than 25% of familial breast cancer. The rest of the cases could be explained by mutations in mainly moderate and low penetrance cancer susceptibility genes together with environmental factors. Many of the genes already associated with breast cancer susceptibility encode proteins that operate together with BRCA1 and BRCA2 in the DNA damage response pathway (DDR) \[[@B3]-[@B7]\]. Other genes with similar functions thus represent good candidates for being new susceptibility genes.

Recent evidence indicates ubiquitin chain formation, recognition and breakdown at the site of DNA double-strand breaks (DSB) as an essential component of the DDR \[[@B8]\]. RNF8 is a RING-finger ubiquitin ligase (E3), which is recruited to the sites of DNA damage after ATM/ATR-dependent phoshorylation of the H2AX histone variant \[[@B9]-[@B11]\]. Together with its ubiquitin-conjugating enzyme (E2) partner UBC13 it mediates K63-linked polyubiquitin conjugation to histones H2A and H2AX. The RNF8/UBC13-dependent histone ubiquitylation is then amplified by the RNF168 E3-ligase acting in concert with UBC13 \[[@B12]\]. Ubiquitynated histones are recognized by RAP80 through its ubiquitin interaction motifs (UIMs), which provide an ubiquitin recognition element to target the BRCA1 E3 ligase, Abraxas, MERIT40, BRCC45 and a K63-ubiquitin specific deubiquitinating enzyme BRCC36 to DSBs. Each of these activities is required for appropriate checkpoint and repair responses to ionizing radiation \[[@B13]-[@B15]\]. Depletion of RNF8 or UBC13 *in vitro*leads to inhibition of the recruitment of 53BP1, BRCA1, RAP80 and Abraxas to DSB sites \[[@B9]-[@B11],[@B16]\]. It has also been demonstrated that the depletion of RNF8 leads to increased ionizing radiation sensitivity and defective G2/M checkpoint \[[@B9]-[@B11]\]. In addition, *Rnf8^-/-^*mice display increased genomic instability and higher risk for tumorigenesis, proposing that RNF8 is a novel tumor suppressor \[[@B17]\].

Besides RNF8, the ubiquitin E2 variant (UEV) MMS2 seems to be essential for certain functions of UBC13. MMS2 forms a complex with UBC13 \[[@B18]\], and this heterodimer formation has been demonstrated to be essential for the DNA damage repair function of UBC13 \[[@B19]\]. Suppression of UBC13 or MMS2 has been shown to increase the sensitivity to DNA damaging agents \[[@B19]\], although the exact role of MMS2 in DDR is still unclear \[[@B20]\].

We have previously reported a potentially deleterious germline variant of *RAP80*(del81E) that abrogated ubiquitin binding and DNA damage response in breast cancer cases \[[@B21]\]. Additionally, recent findings of an extensive genome-wide linkage consortium study suggested an association between the rare allele of single nucleotide polymorphism (SNP) rs8170 in *MERIT40*and an increased propensity for hormone receptor-negative breast cancer, both in the general population and in *BRCA1*mutation carriers \[[@B22]\]. Based on the evidence that several players in the ubiquitin-mediated BRCA1-dependent DDR seem to contribute to breast cancer predisposition (summarized in Table [1](#T1){ref-type="table"}), we decided to examine the role of *RNF8, UBC13*and *MMS2*in familial breast cancer by performing a comprehensive mutation screening of these genes in 123 Northern Finnish breast cancer families.

###### 

Key operators in the BRCA1-dependent ubiquitin -mediated DNA damage recognition pathway and their currently known role in breast cancer predisposition

  --------------------------------------------------------------------------------------------------------
  Gene        Previous studies on the role in breast cancer predisposition   Disease related alterations
  ----------- -------------------------------------------------------------- -----------------------------
  *RNF8*      Not done                                                       \-

  *RNF168*    Not done ^a^                                                   \-

  *UBC13*     Not done                                                       

  *RAP80*     Mutation screening \[[@B21],[@B27]-[@B29]\]                    del81E \[[@B21]\]

  *Abraxas*   Mutation screening \[[@B27],[@B29]\]                           N. I.

  *MERIT40*   Mutation screening \[[@B30]\]\                                 N. I.\
              GWAS \[[@B22]\]                                                rs8170 \[[@B22]\]

  *BRCC45*    Not done                                                       \-

  *BRCC36*    Not done                                                       \-
  --------------------------------------------------------------------------------------------------------

^a^Homozygous mutations in this gene have been demonstrate to result in RIDDLE syndrome \[[@B12]\]

GWAS, genome wide association study; N. I., not identified

Methods
=======

Study population
----------------

Affected index cases of 123 breast cancer families from Northern Finland were screened for germline mutations in the *RNF8, UBC13*and *MMS2*genes. From the studied families, 77 were classified as high-risk ones, defined as follows: 1) three or more cases of breast and/or ovarian cancer in first or second-degree relatives (median age 49 years, variation 37-80 years), or 2) two cases of breast cancer in first- or second-degree relatives, of which at least one with early disease onset (age ≤ 35 years), bilateral disease or multiple primary tumors. Most of the high-risk families presented three or more cancer cases. The remaining 46 families with moderate disease susceptibility indicated two cases of breast cancer in first- or second-degree relatives. Fourteen of the studied index cases had previously been tested positive for known breast cancer-associated germline mutations in *BRCA1*or *BRCA2*(eleven) and *PALB2*(three). DNA samples from anonymous cancer-free female individuals obtained from Finnish Red-Cross blood donors (N = 104-299, depending on the tested mutation), originating from the same geographical region as the studied cancer cases, were used as controls. All patients had given their informed consent for acquisition of pedigree data and blood specimens for the study of cancer susceptibility gene mutations. Approval to perform the study was obtained from the Ethical Board of the Northern Ostrobothnia Health Care District and the Finnish Ministry of Social Affairs and Health.

DNA extraction and mutation analysis
------------------------------------

Genomic DNA was extracted from blood lymphocytes using either the standard phenol-chloroform method or the Puregene D-50K purification kit (Gentra, Minneapolis, MN, USA). Mutation screening of the coding regions and exon-intron boundaries of the *RNF8, UBC13*and *MMS2*genes was carried out by conformation sensitive gel electrophoresis (CSGE) \[[@B23]\], high resolution melting (HRM) analysis \[[@B24]\], or by direct sequencing. Samples with band shifts in CSGE or deviant melt curves in HRM were reamplified and sequenced with Li-Cor IR2 4200-S DNA Analysis system (Li-Cor, Inc., Lincoln, NE, USA) or with capillary sequencing using ABI3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). For Li-Cor the Sequi Therm EXEL II DNA Sequencing Kit-LC (Epicentre Technologies, Madison, WI, USA) and for ABI the Big dye terminator kit v1.1 (Applied Biosystems, Foster City, CA, USA) were used. Chromatograms were interpreted using CodonCode Aligner v. 3.5.4 (Codon Code Corporation, Dedham, MA, USA) and with MEGA4 \[[@B25]\]. Oligonucleotides for CSGE, HRM and sequencing (Table [2](#T2){ref-type="table"}) were designed using Primer3 software \[[@B26]\], based on sequence information obtained from public databases (NC_000006.11, NC_000012.11 and NC_000008.10).

###### 

Primers used for the screening of *RNF8, UBC13*and *MMS2*

  Gene      Exon   Forward primer (5\'-3\')     Reverse primer (5\'-3\')   PCR fragment size (bp)
  --------- ------ ---------------------------- -------------------------- ------------------------
  *RNF8*    1      GCGAGGAGACCTCTCGAATC         TCCTCTCTGCCATTCATTCA       498
            2      TGCTGCTGGTTGATGAGAT          AAATAAAAGTCATTAGGCTTCTG    250
            3a     AAGAAGACGAAAATCATGAAGC       TAATTCATCCAAACTGAATTTCC    294
            3b     CCTTGTCTTTCCCCAAAGAAT        TTACTTGGCTCAAGGGCAGT       242
            3c     AGTGGCCAGTACACCCTCTG         TTCACATTCATAACGGCTTCA      240
            3d     GGTGACCATGTCCAGGATTC         AAGACCACTCTTGCCCTTCC       260
            4      CAGGAGATTTTCCACCTGCT         GGTCATGTGATGCCTGTTTG       271
            5      CAGGCATGTTTGTGGCTAAA         CCTAGCAACCCTTGCACTGT       242
            6      CCTGTCCCATTTTGCATTTT         AAGGGGTGAGCAACTGTTC        197
            7      GCCCTTAAGATGGGATTGTTG        TCCCTTTACTCCTCCCCATT       483
            8      AGGGAAATACAGGCTCCTCA         CAAGTGACTGAGGGCTTCCT       220
  *UBC13*   1      GACTTCCACTCGTGCGTGA          TCCTCAGCACCCGACTTC         264
            2      TTGGGAGATTGGAGCTGTTC         TGGAATGCTTAAGAGAAAAAGGA    430
            3      GTCTGTGGGAGGGAAGTGAA         CCCATAGCAAGCCATTTTGT       385
            4      ATCTTTCAGCCCTGATCCAA         GAGGGGCCACTGCTTTTA         448
  *MMS2*    1      CCCGGCCCTCATGAACTT           GGTCCCAGGCTACGCTCT         411
            2      AGGGGATTTGGTCTTTTTGG         CACGTGGGAAGCATCAATAA       421
            3      GCACTTAGACATTAATATTTTAGGTA   TTTTGGCTTAACAAAGGTCCTC     331
            4      TGCTTAACAAATTGGTGCCATA       GCTGCATTTTTCCTCCTGTT       408

Statistical and bioinformatical analysis
----------------------------------------

Carrier frequencies between patients and healthy controls were compared by using Pearson Chi-Square or Fisher\'s exact test in PASW Statistics (version 18 for Windows, SPSS Inc., Chicago, IL, USA), which was also used for the generation of odds ratios and confidence intervals. All alterations were checked with NNSplice software for potential splicing effects <http://www.fruitfly.org/seq_tools/splice.html>.

Results
=======

The mutation analysis of *RNF8*revealed two exonic, two intronic and three 5\'UTR variants. Only one of these variants was novel (not reported the NCBI SNP database, <http://www.ncbi.nlm.nih.gov/SNP/>). Both of the observed exonic variants of *RNF8*were synonymous. In the *UBC13*gene, one unreported and one known intronic variant were observed, whereas no sequence alterations were observed in *MMS2*. All observed alterations in *RNF8*and *UBC13*were assessed for possible effects on consensus splice sites, but none of them had a predicted effect on splicing. In order to evaluate possible pathogenicity of the observed changes, their frequencies were compared between cases and healthy control individuals. None of the found sequence changes, however, appeared to associate with breast cancer susceptibility (Table [3](#T3){ref-type="table"}).

###### 

Observed alterations in the *RNF8*,*UBC13*and *MMS2*genes in Finnish breast cancer families

  --------------------------------------------------------------------------------------------------------
  Gene      Nucleotide change       rs number    Carrier frequency   P-value           
  --------- ----------------------- ------------ ------------------- ----------------- -------------------
  *RNF8*    *RNF8*ex1-36 C \> T\    \-           4.8% (6/123)        1.9% (2/104)      0.29\
            (5\'-UTR)                                                                  (2.6; 0.52-13.2)

            *RNF8*ex1-150 G \> T\   rs4714059    12.2% (15/123)      19.2% (20/104)    0.20\
            (5\'-UTR)                                                                  (0.58; 0.28-1.21)

            *RNF8*ex1-134 C \> G\   rs195420     22.8% (28/123)      18.3% (19/104)    0.42\
            (5\'-UTR)                                                                  (1.32; 0.69-2.53)

            *RNF8*ex4+17 A \> G\    rs77440008   1.6% (2/123)        5.9% (16/273)     0.07\
            (intron)                                                                   (0.27; 0.06-1.17)

            *RNF8*ex7-6 C \> T\     rs2284923    41.5% (51/123)      46.7% (121/259)   0.38\
            (intron)                                                                   (0.81; 0.52-1.25)

            *RNF8*ex7 G1344A\       rs2284922    36.6% (45/123)      41.1% (111/270)   0.44\
            (Thr448Thr)                                                                (0.83; 0.53-1.28)

            *RNF8*ex7 G1377A\       rs34150698   17.9% (22/123)      19.3% (52/270)    0.78\
            (Lys459Lys)                                                                (0.91; 0.53-1.59)

                                                                                       

  *UBC13*   *UBC13*ex3+17C \> T\    rs7969431    3.3% (4/123)        4.7% (14/299)     0.61\
            (intron)                                                                   (0.68; 0.22-2.12)

            *UBC13*ex4-18 G \> T\   \-           1.6% (2/123)        3.4% (10/297)     0.52\
            (intron)                                                                   (0.47; 0.10-2.20)

  *MMS2*    \-                      \-           \-                  \-                \-
  --------------------------------------------------------------------------------------------------------

OR, Odds ratio; CI, confidence interval; UTR, untranslated region

Discussion
==========

RNF8, UBC13 and MMS2 have important roles in the maintenance of genomic integrity and cell-cycle checkpoint control \[[@B9]-[@B11],[@B19]\]. Based on their involvement in DDR and importance in BRCA1-mediated DNA damage recognition it was considered possible that mutations in these genes might contribute to hereditary predisposition to breast cancer.

In the current study, the whole coding region of the *RNF8, UBC13*and *MMS2*genes was systematically screened for mutations in 123 breast cancer families. No deleterious sequence alterations were observed in any of the genes. Previous studies have suggested that the *RNF8*gene could be novel tumor suppressor \[[@B17]\], but it seems that germline mutations predisposing to breast cancer in this gene do not exist or, at least, are very rare. It is of interest that another E3 ligase, RNF168, which acts together with UBC13 to amplify the RNF8-dependent histone ubiquitylation has been shown to be defected in RIDDLE syndrome, which is an immunodeficiency and radiosensitivity disorder. However, it is still unclear whether RIDDLE syndrome is associated with genome instability or increased tumor incidence \[[@B12]\].

Conclusion
==========

The present data suggest that mutations predisposing to breast cancer are either very rare or absent in the coding region of the *RNF8, UBC13*and *MMS2*genes, which could possibly point to the essentiality of their protein products in the DNA damage response and other functions maintaining genomic integrity. Although a small study like this cannot exclude the possibility of some other rare mutations in *RNF8, UBC13*and *MMS2*might predispose to breast cancer, based on our findings they unlikely make any sizeable contribution to cancer predisposition. To our knowledge, this is the first study reporting the mutation screening of the *RNF8, UBC13*and *MMS2*genes in familial breast cancer cases.
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